ARVN

TentativeAI Memo

Arvinas

As of 2026-10-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

ARV-393 Phase 1 lymphoma data • 2026-12-31

Base target: $8 / p=45% prob

Biggest risk

Arvinas explicitly says the ARV-102 study was not designed to assess clinical efficacy. Small, early studies may fail to translate into durable benefit; ARV-806 also depends on finding a partner for further development. Arvinas ARV-102 release [#SEC-8K-2026-08-04]

Invalidation

Break below $4 or thesis failure.

What would change my mind?

The October 7 ARV-102 presentation reported dose-related exploratory oculomotor changes and associated LRRK2 biomarker reductions in 24 Parkinson’s patients. Alongside the planned ARV-393 and ARV-806 readouts, this supports a tentative positive monitoring view—not a demonstrated clinical-efficacy thesis. Arvinas ARV-102 release

Research note

Recommendation

—

Confidence

medium

As of

2026-10-14

Base target

p=45%

Bull target

$11

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

ARV-027 muscle-degradation readout
The October 7 ARV-102 presentation reported dose-related exploratory oculomotor changes and associated LRRK2 biomarker reductions in 24 Parkinson’s patients.
Alongside the planned ARV-393 and ARV-806 readouts, this supports a tentative positive monitoring view—not a demonstrated clinical-efficacy thesis.

BearKey bullets

ARV-102 biomarker and oculomotor findings do not establish clinical efficacy; the Parkinson’s study included 24 patients treated for 28 days.
Arvinas ARV-102 release
ARV-393 and ARV-806 remain early-phase programs exposed to efficacy, safety, enrollment and readout-timing risk.

WatchKey bullets

ARV-393 Phase 1 lymphoma data

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $8 (p=45%)

Target spread vs base: +47% / -53%

Scenario probabilities

Bull Target: $11 (p=30%)Base Target: $8 (p=45%)Bear Target: $4 (p=25%)

Commentary

The October 7 ARV-102 presentation has occurred, so it is no longer an upcoming catalyst. Company-reported exploratory findings are encouraging but not efficacy evidence. The packet does not establish a price move attributable to that release, post-release analyst revisions, or reliable social, options, short-interest or employee-sentiment measurements; zero-valued fields denote unavailable data, not neutral readings. The deterministic positive prior supports monitoring, while low coverage and early clinical evidence limit conviction. Arvinas ARV-102 release

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

ARV-027 muscle-degradation readout

Scenarios

Bull Target (Scenario probability)

$11 / p=30% prob

Base Target (Scenario probability)

$8 / p=45% prob

Bear Target (Scenario probability)

$4 / p=25% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
ARV-393 Phase 1 lymphoma data
Arvinas plans to present early monotherapy data in relapsed/refractory non-Hodgkin lymphoma in 2H 2026. Responses reported in early dose-escalation cohorts are preliminary; durability, safety and activity at effective exposure remain open questions. The date is the end of management’s window, not a confirmed presentation date. [#SEC-8K-2026-08-04] SEC earnings exhibit
Prob 65.00% • Move 20.00% • Priced-in 35.00%
EVENT2026-12-31
ARV-806 initial data and licensing decision
Initial KRAS G12D Phase 1 monotherapy data remain planned for 2H 2026. Arvinas intends to seek a licensee for further trials, so clinical results and any eventual deal terms both matter; no transaction is assured. The date is the end of the stated data window. [#SEC-8K-2026-08-04] SEC earnings exhibit
Prob 55.00% • Move 15.00% • Priced-in 25.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

ARV-027 muscle-degradation readout
2027-06-30
Arvinas plans initial Phase 1 healthy-volunteer data on androgen-receptor degradation in muscle in 1H 2027. Target engagement would be an early development step, not proof of benefit in Kennedy’s disease. The date marks the end of management’s window. [#SEC-8K-2026-08-04] SEC earnings exhibit
Prob 60% • Move 12% • Priced-in 20%

Risks

ARV-102 biomarker and oculomotor findings do not establish clinical efficacy; the Parkinson’s study included 24 patients treated for 28 days. Arvinas ARV-102 release
ARV-393 and ARV-806 remain early-phase programs exposed to efficacy, safety, enrollment and readout-timing risk. [#SEC-8K-2026-08-04]
The $567.9 million June 30 cash-and-securities balance was down $117.5 million from year-end 2025; management’s runway into 2H 2028 depends on its current operating plan. [#SEC-8K-2026-08-04] SEC earnings exhibit
The planned ARV-806 out-license may not occur or may carry less favorable economics than investors expect. [#SEC-8K-2026-08-04]

Peers

Symbol	Summary
ALLO	Similar-size clinical biotech in the packet, but its programs are not verified as direct ARVN comparables. Use only as a broad clinical-event-risk reference.
RZLT	Similar-size biotech in the packet, but indication and asset economics are not established as comparable. It does not support a direct valuation multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

ALLO

Similar-size clinical biotech in the packet, but its programs are not verified as direct ARVN comparables. Use only as a broad clinical-event-risk reference.

RZLT

Similar-size biotech in the packet, but indication and asset economics are not established as comparable. It does not support a direct valuation multiple.